These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Somatic PIK3CA mutations as a driver of sporadic venous malformations. Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594 [TBL] [Abstract][Full Text] [Related]
4. A xenograft model for venous malformation. Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783 [TBL] [Abstract][Full Text] [Related]
5. Genetic landscape of common venous malformations in the head and neck. Du Z; Liu JL; You YH; Wang LZ; He J; Zheng JW; Zhang ZY; Wang YA J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):1007-1016.e7. PubMed ID: 33248299 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive phenotypic and genomic characterization of venous malformations. Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816 [TBL] [Abstract][Full Text] [Related]
7. CD10 and CD34 as markers in vascular malformations with PIK3CA and TEK mutations. Moneghini L; Tosi D; Graziani D; Caretti A; Colletti G; Baraldini V; Cattaneo E; Spaccini L; Zocca A; Bulfamante GP Hum Pathol; 2020 May; 99():98-106. PubMed ID: 32272124 [TBL] [Abstract][Full Text] [Related]
8. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118 [TBL] [Abstract][Full Text] [Related]
9. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations. Si Y; Huang J; Li X; Fu Y; Xu R; Du Y; Cheng J; Jiang H Cell Commun Signal; 2020 Aug; 18(1):139. PubMed ID: 32867785 [TBL] [Abstract][Full Text] [Related]
10. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation. Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708 [TBL] [Abstract][Full Text] [Related]
11. Development of Molecular Therapies for Venous Malformations. Kangas J; Nätynki M; Eklund L Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117 [TBL] [Abstract][Full Text] [Related]
12. A Patient-Derived Xenograft Model for Venous Malformation. Schrenk S; Goines J; Boscolo E J Vis Exp; 2020 Jun; (160):. PubMed ID: 32597867 [TBL] [Abstract][Full Text] [Related]
13. Functional assessment of two variants of unknown significance in TEK by endothelium-specific expression in zebrafish embryos. Bell LM; Holm A; Matysiak U; Driever W; Rößler J; Schanze D; Wieland I; Niemeyer CM; Zenker M; Kapp FG Hum Mol Genet; 2021 Dec; 31(1):10-17. PubMed ID: 34254124 [TBL] [Abstract][Full Text] [Related]
14. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. Boscolo E; Limaye N; Huang L; Kang KT; Soblet J; Uebelhoer M; Mendola A; Natynki M; Seront E; Dupont S; Hammer J; Legrand C; Brugnara C; Eklund L; Vikkula M; Bischoff J; Boon LM J Clin Invest; 2015 Sep; 125(9):3491-504. PubMed ID: 26258417 [TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Limaye N; Wouters V; Uebelhoer M; Tuominen M; Wirkkala R; Mulliken JB; Eklund L; Boon LM; Vikkula M Nat Genet; 2009 Jan; 41(1):118-24. PubMed ID: 19079259 [TBL] [Abstract][Full Text] [Related]
16. Common and specific effects of TIE2 mutations causing venous malformations. Nätynki M; Kangas J; Miinalainen I; Sormunen R; Pietilä R; Soblet J; Boon LM; Vikkula M; Limaye N; Eklund L Hum Mol Genet; 2015 Nov; 24(22):6374-89. PubMed ID: 26319232 [TBL] [Abstract][Full Text] [Related]
17. Ponatinib Combined With Rapamycin Causes Regression of Murine Venous Malformation. Li X; Cai Y; Goines J; Pastura P; Brichta L; Lane A; Le Cras TD; Boscolo E Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):496-512. PubMed ID: 30626204 [TBL] [Abstract][Full Text] [Related]
18. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059 [TBL] [Abstract][Full Text] [Related]
19. A Xenograft Model for Venous Malformation. Goines J; Boscolo E Methods Mol Biol; 2021; 2206():179-192. PubMed ID: 32754818 [TBL] [Abstract][Full Text] [Related]